Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  UnitedHealth Group    UNH

UNITEDHEALTH GROUP

(UNH)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

UnitedHealth : FTC Approves UnitedHealth's $4.3 Billion Purchase of DaVita Physicians Group

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/19/2019 | 04:17pm EDT

By Patrick Thomas

Federal regulators approved UnitedHealth Group Inc.'s $4.3 billion purchase of DaVita Inc.'s physician group with the condition that the UnitedHealth sell one of its newly purchased health-care provider organizations in Nevada.

The Federal Trade Commission said Wednesday UnitedHealth has agreed to divest a primary-care practice in the Las Vegas region known as HealthCare Partners Nevada to Utah-based Intermountain Healthcare.

UnitedHealth's proposed deal to acquire one of the nation's biggest doctor groups was announced in December 2017, the same week as pharmacy giant CVS Health Corp. agreed to buy insurer Aetna Inc.

DaVita bought medical group HealthCare Partners LLC in 2012 for $4.42 billion in a deal that diversified it away from its core kidney-care business. At the time, HealthCare Partners was the largest U.S. operator of physician groups and networks. DaVita later expanded it.

The FTC alleged the UnitedHealth-DaVita deal would create a monopoly in the Las Vegas area and that the combination would have resulted in higher health-care costs and weaker competition for on quality, services and other amenities.

UnitedHealth's Optum health-services arm said in a statement that with DaVita Medical Group, it will serve a combined 16 million patients. DaVita Medical Group had about 763,000 members in various states at the end of 2017, according to the company's latest proxy.

"Together we will improve patient health and experiences while lowering costs across the continuum of care -- including primary, specialty, urgent and surgical care," said Andrew Witty, CEO of Optum, in a statement.

Following the deal with UnitedHealth, DaVita will continue to operate its kidney-care services business. DaVita serves 203,500 patients at 2,689 outpatient dialysis centers in the U.S. and operates 234 dialysis centers in nine other countries.

Stocks mentioned in the article
ChangeLast1st jan.
DAVITA INC. 0.51% 57.01 Delayed Quote.10.22%
UNITEDHEALTH GROUP -0.67% 236.99 Delayed Quote.-11.45%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on UNITEDHEALTH GROUP
09:32aUNITEDHEALTH : Thinking about trading options or stock in Facebook, IBM, JPMorga..
PR
02:48aWHAT'S NEWS : Business & Finance -- WSJ
DJ
02:48aUNITEDHEALTH : Lifts Outlook as Sales Rise
DJ
10/15ASIA MARKETS: Asian Markets Mostly Gain After Positive Start To U.S. Earnings..
DJ
10/15Health-Care Stocks Get a Welcome Respite -- Update
DJ
10/15WALL STREET STOCK EXCHANGE : U.S. Stocks Rise on Strong Earnings Start
DJ
10/15JPMorgan, J&J rise; American Tower, Whiting Petroleum fall
AQ
10/15MARKET SNAPSHOT: Dow Closes At 3-week High As Investors Cheer Start To Earnin..
DJ
10/15UNITEDHEALTH : Raises Profit Targets on Higher Sales -- Update
DJ
10/15WALL STREET STOCK EXCHANGE : U.S. Stocks Climb as Earnings Season Kicks Off
DJ
More news
Financials (USD)
Sales 2019 243 B
EBIT 2019 19 499 M
Net income 2019 13 678 M
Debt 2019 30 623 M
Yield 2019 1,74%
P/E ratio 2019 16,7x
P/E ratio 2020 15,1x
EV / Sales2019 1,05x
EV / Sales2020 0,96x
Capitalization 225 B
Chart UNITEDHEALTH GROUP
Duration : Period :
UnitedHealth Group Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends UNITEDHEALTH GROUP
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Average target price 285,88  $
Last Close Price 236,99  $
Spread / Highest target 31,7%
Spread / Average Target 20,6%
Spread / Lowest Target 1,27%
EPS Revisions
Managers
NameTitle
David Scott Wichmann Chief Executive Officer & Director
Stephen J. Hemsley Executive Chairman
John Franklin Rex Chief Financial Officer & Executive Vice President
Richard J. Migliori Chief Medical Officer & EVP-Medical Affairs
Ken Ehlert Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
UNITEDHEALTH GROUP-11.45%226 107
ANTHEM, INC.-5.21%63 683
CIGNA CORPORATION-15.67%60 478
HUMANA-3.43%37 371
CENTENE CORPORATION-21.58%18 699
WELLCARE HEALTH PLANS13.38%13 468